Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
substantial rise in epileptic threshold was found after systemic (intraperitoneal) injection of high doses (600 or 1200 mg/kg) of vigabatrin. Bilateral microinjection of vigabatrin (10 μg) into the anterior or posterior substantia nigra pars reticulata also improved the seizure threshold, but not as dramatically as systemic therapy. Local delivery to the subthalamic nucleus (STN) increases the epileptic threshold more dramatically than intranigra or systemic treatment of vigabatrin [1].
|
---|---|
ln Vivo |
In Caco-2 and MDCK cells, vigabatrin at 30 mM reduced taurine uptake by 34% and 53%, respectively. Vigabatrin absorption in Caco-2 cells is concentration-dependent and saturable at neutral pH, with a Km value of 27 mM. In renal and intestinal cell culture models, vigabatrin decreases the absorption of taurine [2].
|
References |
[1]. Broeer, et al. Vigabatrin for focal drug delivery in epilepsy: Bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. Neurobiology of Disease (2012), 46(2), 362-376.
[2]. Jakob Plum, et al. The anti-epileptic drug substance vigabatrin inhibits taurine transport in intestinal and renal cell culture models. Int J Pharm. 2014 Oct 1;473(1-2):395-7. [3]. Gaily, Eija Vigabatrin monotherapy for infantile spasms. Expert Review of Neurotherapeutics (2012), 12(3), 275-286. |
Molecular Formula |
C6H11NO2
|
---|---|
Molecular Weight |
129.15704
|
CAS # |
68506-86-5
|
Related CAS # |
Vigabatrin hydrochloride;1391054-02-6
|
SMILES |
C=CC(N)CCC(O)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~50 mg/mL (~387.12 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (774.23 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 7.7423 mL | 38.7117 mL | 77.4234 mL | |
5 mM | 1.5485 mL | 7.7423 mL | 15.4847 mL | |
10 mM | 0.7742 mL | 3.8712 mL | 7.7423 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.